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Abstract 
Metformin  is  a  dimethyl  biguanide  oral
anti-hyperglycemic agent. Lactic acidosis due
to  metformin  is  a  fatal  metabolic  condition
that limits its use in patients in poor clinical
condition, consequently reducing the number
of patients who benefit from this medication.
In a double blind randomized clinical trial, we
investigated 200 type 2 diabetic patients after
coronary  artery  bypass  surgery  in  the  open
heart ICU of the Mazandaran Heart Center,
and randomly assigned them to equal inter-
vention and control groups. The intervention
group received regular insulin infusion along
with 2 metformin 500 mg tablets every twelve
hours, while the control group received only
intravenous  insulin  with  2  placebo  tablets
every  twelve  hours.  Lactate  level,  pH,  base
excess,  blood  glucose  and  serum  creatinine
were measured over five 12 h periods, with
data  averaged  for  each  period.  The  primary
outcome in this study was high lactate levels.
Comparison between the 2 groups was made
by  independent  Student’s  t-test.  To  compare
changes in multiple measures in each group
and analysis of group interaction, a repeated
measurement ANOVA test was used.
There  was  no  significant  difference
between  the  2  groups  regarding  pH,  base
excess,  or  bicarbonate  intake  (P>0.05).  No
patient showed lactic acidosis in either group.
Lactate levels were 23.0 vs 23.4 in the insulin-
metformin and insulin only groups when the
study was started, respectively. At the end of
the  study,  those  levels  were  18.7  vs 18.9,
respectively. In addition, the ANOVA repeated
measurement test did not show a significant
difference in terms of changes in the amount
of lactate level between the 2 groups during
the five measurement tests of the study period
(P>0.05).
High-dose metformin (1,000 mg twice daily
with insulin) does not cause lactic acidosis in
type 2 diabetic patients after coronary artery
bypass surgery.
Introduction
Coronary artery bypass surgery (CABG) is
the most common heart surgery. In the United
States,  515,000  patients  undergo  coronary
artery bypass surgery (CABG) each year; about
28% of them have diabetes.1
Hyperglycemia  (blood  glucose  over  200
mg/dL) is common in patients in a poor clini-
cal  condition.  This  causes  more  infection,
ischemic events, renal and neurological com-
plications, and higher mortality.2,3 The main
mechanism of increased blood glucose in this
condition is insulin resistance (IR); therefore,
insulin is considered to be the main drug for
treatment of hyperglycemia. However, insulin
accelerates  the  transfer  of  potassium  and
magnesium  into  the  cells  that  may  lead  to
hypokalemia  and  hypomagnesia.4,5 In  addi-
tion,  due  to  insulin  resistance  and  insulin
induced  hypoglycemia,  the  use  of  products
such  as  metformin,  which  does  not  cause
hypoglycemia, is recommended for blood glu-
cose  control  in  patients  with  insulin  resist-
ance.4
Metformin  was  introduced  in  the  United
States in 1995. It is a dimethyl biguanide oral
anti-hyperglycemic drug that reduces overall
mortality  in  type  2  diabetes.6 Metformin
reduces gluconeogenesis and glycogenolysis,
and increases sensitivity of insulin receptors
through multiple mechanisms. In addition, it
reduces the level of serum lipids and lipopro-
teins. In particular, it reduces stroke (41%)
and heart attacks (39%).7
Metformin  has  different  mechanisms  of
action  from  other  anti-hyperglycemic  drugs
and does not lead to a severe drop in the blood
glucose  level  of  diabetic  patients.7 Between
the years 1985 to 2001, 66 cases of metformin-
associated lactic acidosis (MALA) were report-
ed by the FDA and 48 cases by the Australian
Adverse Drug Reactions Advisory Committee
(ADRAC).8MALA is a fatal metabolic condition
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that limits metformin use in patients in poor
clinical condition.9 These restrictions consid-
erably  reduce  the  number  of  patients  who
could benefit from this advantageous drug.10
However, Salpeter et al.6 have estimated the
incidence of lactic acidosis in type 2 diabetic
metformin  users  to  be  less  than  non-met-
formin  users  (0.0043%  vs 0.0054%).  These
results  are  similar  to  those  of  Stang  et  al.
(0.002-0.009% vs 0.009%).5 This clinical trial
was  performed  to  determine  whether  met-
formin can create lactic acidosis in type 2 dia-
betic  patients  after  CABG  surgery.  Whereas
previous studies have taken a descriptive or
retrospective  approach  with  different  times/
dose of metformin, to our knowledge, this is
the  first  clinical  trial  studying  the  effect  of
metformin administration in such patients.
Materials and Methods
In  this  double  blind  randomized  clinical
trial, 200 type 2 diabetic patients were studied
following CABG surgery in the open heart ICU
of  the  Mazandaran  Heart  Center.  Approval
from  the  Ethics  Committee  of  Mazandaran
University of Medical Sciences and informed
consent from patients were obtained. Patients
were randomly and simultaneously assigned to
2 groups; 100 patients received insulin and 100
received insulin-metformin.
Inclusion criteria were: age between 35 to
75  years,  type  2  diabetes,  non-emergency
CABG  surgery,  the  use  of  cardiopulmonary
pump during the operation and hemodynamic
stability  (MAP  >  60,  lack  of  dangerous  dys-
rhythmia and heart rate between 50 to 100). 
We excluded patients with any kind of liver
disorder (SGPT and SGOT more than 75), renal
dysfunction (serum creatinine more than 1.5
mg/dL  in  2  consecutive  tests),  heart  failure
(ejection fraction ratio less than 30%), and the
use of any contrast or history of angiography
within  two  days  before  the  operation.
Medication would be interrupted and patients
would leave the study if at any time during the
study  the  following  events  were  recorded:
serum  lactate  level  more  than  45  mg/dL  (5
mmol/L) or had values which increased more
than 18 mg/dL (2 mmol/L) compared to previ-
ous levels, pH less than 7.25 or serum base
excess (BE) of less than -6 mmol/L, mean arte-
rial oxygen pressure less than 60 mmHg in two
consecutive  Arterial  Blood  Gas  (ABG)  tests,
potassium drops of less than 3 meq/L, nausea
and  vomiting,  use  of  metformin  metabolism
inhibitors such as amiodarone and cimetidine,
use of high-dose inotrope drugs more than 3 h
after extubation and need for reoperation for
any reason. Patients who qualified for study
entry were randomly assigned to one of these
groups.
Insulin  group:  regular  insulin  infusion
based on the center protocol with 2 placebo
tablets (Sari pharmaceutical laboratory, Iran)
every 12 h. Insulin-metformin group: regular
insulin infusion based on the center protocol
with 2 metformin tablets 500 mg (Aria, Iran)
every 12 h.
Metformin or placebo were prescribed 3 h
after extubation by oral administration and in
the absence of oral tolerance through a naso-
gastric tube. All oral anti-hyperglycemic drugs
were discontinued two days before the surgery
in all patients and subsequent blood glucose
levels were controlled with insulin. There was
no  difference  in  onset  of  intervention  or
patient diet before and after surgery between
the 2 groups (diabetic and cardio diet based on
hospital  routine).  Patients  were  placed  in
treatment  protocols  for  60  h  during  which
blood glucose, lactate, pH and BE were meas-
ured every 2 h and creatinine was measured
daily. The study was divided into 5 stages and
the mean 12 h period values were calculated.
Blood glucose, lactate, pH and BE were meas-
ured  by  advanced  Blood  Gas  machine  GEM
3000 (Instrumen  tation Laboratory, MA, USA)
using future pulse medical company cartridge.
Serum  creatinine  was  measured  by  Auto
Analyzer Ebra XL640 model and Pars Company
Cartridge. This was a double blind study and
none of the patients, physicians, nurses or lab-
oratory staff was aware of the type of treatment
received. 
Primary outcome in this study was blood lac-
tate  levels.  An  acceptable  range  of  arterial
blood lactate level is 4.5-13.5 mg/dL. Blood glu-
cose level, pH and BE were assessed as second-
ary outcomes. In this study, acidosis and hypo-
glycemia were considered to be complications.
After collecting and classifying data, statistical
analyses were carried out by SPSS 16 software.
Qualitative variables were evaluated with the
χ2test. After controlling the normal distribu-
tion of numerical variables by the Kolmogorov-
Smirnov test, an independent student's t-test
was calculated to compare the two groups. To
compare  changes  in  multiple  measurements
in each group and to analyze group interaction,
a  repeated  measurement  ANOVA  test  was
used. In all statistical tests, the significance
level was considered to be 0.05.
Results
Two hundred patients were entered in this
clinical trial; 100 patients in the insulin group
and  100  patients  in  the  insulin-metformin
group (using an equal randomized allocation).
Ten patients were excluded during the project
and  data  from  190  patients  were  analyzed
(Figure 1).
Forty-six of 96 patients (52.1%) among the
insulin group and 50 of 94 patients (46.8%)
among the insulin-metformin group were men
but the difference was not statistically signifi-
cant (P>0.05).
Also  there  was  no  statistically  significant
difference in the basic and clinical characteris-
tics between the 2 groups (Table 1).
Lactic acidosis was not observed in either of
the study arms. In patients receiving insulin,
at  baseline  the  serum  lactate  level  was
23.4±10.1 (mg/dL), while at the end of study, it
reached 18.9±5.9 (a 19% reduction). Similarly,
an approximately 19% reduction in serum lac-
tate  level  was  seen  in  the  metformin  group
(Figure 2).
Changes in pH and BE were similar in both
groups with no statistically significant differ-
ence  (F(1,  187)=0.286;  P=0.853  for  pH  and
F(1, 187)=0.159; P=0.932) for BE (Figure 3).
Average consumed bicarbonate during the
study was 6.77 meq (95%CI: 4.07 to 9.470) in
the insulin group and 6.91meq (95%CI: 3.97 to
Table 1. Pre-operative patient characteristics.
Insulin group  Insulin-metformin P
(n=96) Group (n=94) (t-test)
Mean 95% CI Mean 95% CI
Age (Y) 60.5 59.2 to 61.8 59.8 58.3 to 61.2 0.435
Weight (kg) 66.4 64.4 to 68.4 67.8 65.7 to 70.0 0.350
Height (m) 1.62 1.60 to 1.64 1.63 1.61 to 1.65 0.367
Body mass index (kg/m2) 25.3 24.6 to 26.1 25.4 24.6 to 26.3 0.844
Mean arterial pressure (mm/Hg) 71.3 70.0 to 72.5 73.3 71.5 to 75.2 0.072
Ejection fraction (%) 46.5 44.7 to 48.2 47.1 45.6 to 48.5 0.585
Intubation time (hr) 5.47 5.33 to 5.62 5.32 5.18 to 5.46 0.150
Lactate (mg/dL) 23.4 25.5 to 21.4 23.0 25.0 to 21.1 0.793
pH 7.353 7.359 to 7.346 7.357 7.364 to 7.350 0.392
Base excess (mmol/L) -3.68 -3.48 to -3.89 -3.61 -3.40 to -3.81 0.606
Serum creatinine 0.89 0.93 to 0.85 0.92 0.95 to 0.87 0.426
Potassium (meq/L) 4.32 4.38 to 4.26 4.37 4.42 to 4.32 0.235Article
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9.86) in the insulin-metformin group. There
was no significant difference between the 2
groups (t= -0.072; P=0.943).
No significant difference was observed in
the  number  of  high  blood  lactate  events
(between 30-45 mg/dL) during the study in the
insulin group and the insulin-metformin group
(χ2=0.850; P=0.467) (Figure 4).
Average  blood  glucose  of  patients  in  both
groups decreased during the study. However,
the  reduction  observed  in  the  insulin-met-
formin group was more than the insulin group
and this difference was statistically significant
(F(1, 187) =9.873; P<0.001).
Discussion and Conclusions
The study findings showed that use of met-
formin (1,000 mg/BD) together with insulin in
type 2 diabetic ICU patients after CABG surgery
did not cause lactic acidosis. Blood lactate lev-
els in both groups gradually decreased during
the study, but we observed no significant differ-
ence between the 2 groups. There was no sig-
nificant difference in blood pH between the 2
groups during the study period and mean blood
pH in patients were in the normal range (7.35-
7.45). No dangerous reduction or increase in
blood pH occurred. Some cases of lactic acido-
sis  caused  by  metformin  were  reported  by
Preiser and Vincet,11 Lustik et al.,12 Silvestre et
al.,13 Ashall and Dawes,14 and Cezure et al.,15
that led to stricter limits in the use of met-
formin  in  type  2  diabetic  patients.  However,
Lalau and Race16and Kamber17have stated that
lactic acidosis cannot be directly attributed to
metformin use. Their rationale was that many
patients  who  developed  lactic  acidosis  while
taking  metformin  were  those  who  suffered
from underlying problems such as heart failure,
kidney and liver diseases, and diabetes, which
are  known  as  risk  factors  of  lactic  acidosis.
Duncan  et  al.  showed  that  type  2  diabetic
patients  treated  with  metformin  would  not
develop more severe acidosis. Also long-term
intubation, infection and overall morbidity in
the  metformin  group  were  significantly  less
than  the  non-metformin  group.18 In  the
Duncan et al. study, serum lactate level was
measured  only  in  patients  with  primary  dis-
eases, while the exact dose and the last dose of
metformin were not clear and metformin was
continued up to cardiac surgery. Importantly,
the  present  study  showed  that  the  use  of
insulin along with high-dose metformin, even
immediately after cardiac surgery, does not cre-
ate acidosis, but improves blood glucose control
in these patients.
Our results in a larger number of patients
confirmed the study by Mojtahedzadeh et al.
which  showed  no  significant  relationship
between plasma level of metformin, blood lac-
tate and pH. Also blood pH was in the normal
range and no pH less than 7.3 was seen.19 We
showed that the use of 1,000 mg metformin
twice daily plus insulin does not cause lactic
acidosis  in  type  2  diabetic  patients,  while
there  was  no  difference  in  the  amount  of
bicarbonate prescribed to each of the 2 groups.
Importantly, no lactic acidosis occurred follow-
ing high-dose metformin in patients undergo-
ing  CABG  with  cardiopulmonary  pump  who
have a higher potential risk of lactic acidosis.
Ansari  showed  that  taking  metformin  with
insulin in ICU patients did not cause acidosis,
which  is  consistent  with  the  results  of  this
study.20 Therefore, based on the current pub-
lished data and results of the present study, it
seem that metformin administration in post-
operative or critically injured patients is not
absolutely contraindicated, but rather benefi-
cial, particularly if selected for those patients
with  satisfactory  hepatic,  renal  and  cardiac
function, and as long as these parameters are
appropriately monitored.21 Lactic acidosis due
to metformin is easily preventable by avoiding
dehydration,  especially  in  concomitant
nephrotoxic  drug  use.22 This  study  showed
that high-dose metformin along with appropri-
ate monitoring of renal and liver function not
only protects against but also reduces micro-
vascular complications and deaths from car-
diovascular disease, even after coronary artery
surgery in type 2 diabetic patients.23 During
the present study, after frequent monitoring of
the patients in the ICU, a patient was exclud-
ed due to a creatinine level higher than 1.5
(UNIT) on 2 consecutive tests. On the other
hand, blood glucose level in the metformin-
insulin  group  was  reduced  more  than  the
Figure 1. Flow dia-
gram  of  patients’
randomization,
intervention  and
analysis.
Figure 2. Changes in
blood  lactate  level
(mean and SEM) of
patients  in  insulin
and  insulin-met-
formin  groups  dur-
ing the study.Article
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insulin group. This result suggests the posi-
tive effect of metformin in the control of blood
glucose in type 2 diabetic patients undergoing
CABG surgery, which is probably due to the
metformin effect on the insulin resistance of
these  patients.  This  is  consistent  with  the
findings of previous studies.19
Use  of  metformin  in  type  2  diabetic  ICU
patients after CABG surgery is associated with
better glucose control without theoccurrence of
lactic acidosis. Consequently, it is a safe and
effective drug and, so, a good choice for control-
ling blood glucose in order to reduce the com-
plications  and  improve  survival  in  these
patients.
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